| 產品名稱 |
PL45 |
| 商品貨號 |
B165512 |
| Organism |
Homo sapiens, human |
| Cell Type |
Epithelial |
| Product Format |
frozen |
| Morphology |
adherent with some rounded floating cells |
| Culture Properties |
adherent |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
ductal adenocarcinoma |
| Age |
adult |
| Gender |
male |
| Ethnicity |
White |
| Applications |
Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. PL45 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the pancreas of a man with poorly differentiated pancreatic adenocarcinoma of ductal origin. The line expresses wild-type DPC4 and BRCA2 genes. The PL45 cell line was derived from the same patient as the Panc 10.05 cell line (ATCC CRL-2547). |
| Storage Conditions |
liquid nitrogen vapor phase |
| Derivation |
PL45 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the pancreas of a man with poorly differentiated pancreatic adenocarcinoma of ductal origin. The PL45 cell line was derived from the same patient as the Panc 10.05 cell line (ATCC CRL-2547). |
| Clinical Data |
White adult male PL45 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the pancreas of a man with poorly differentiated pancreatic adenocarcinoma of ductal origin. The PL45 cell line was derived from the same patient as the Panc 10.05 cell line (ATCC CRL-2547). |
| Oncogene |
BRCA2 +; DPC4 +; K-ras +; p53 + |
| Genes Expressed |
BRCA2 +; DPC4 +; K-ras +; p53 + |
| Comments |
The MTS1 gene on chromosome 9p21 encodes the p16 inhibitor of cyclinD/CDK4 complexes. PL45 cells have a wild-type p16 gene. This gene is transcriptionally silenced and methylated in PL45 cells. PL45 cells have a wild-type cyclin-dependent kinase (CDK4) gene. Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. The line expresses wild-type DPC4 and BRCA2 genes. The line has a p53 gene mutation at codon 255 where an ATC --> AAC mutation resulted in substitution of asparagine for isoleucine. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Protocol: - Remove and discard culture medium.
-
Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
-
Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach.
Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. -
Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
-
Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:6 is recommended Medium Renewal: Every 2 to 3 days |
| Cryopreservation |
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| STR Profile |
Amelogenin: X CSF1PO: 12 D13S317: 12 D16S539: 9,12 D5S818: 13 D7S820: 8,9 THO1: 6,9.3 TPOX: 11 vWA: 16 |
| Name of Depositor |
SE Kern |
| Deposited As |
human |
| Year of Origin |
1992 |
| References |
Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
Caldas C, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8: 27-32, 1994. PubMed: 7726912
Su GH, et al. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc. Natl. Acad. Sci. USA 98: 3254-3257, 2001. PubMed: 11248065
|
